Bristol Myers Squibb helped the cell encapsulation technology developer raise cash that will help fund its international growth.
Author: Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Exscientia explores Nasdaq IPO
Dundee spinout Exscientia has filed for an offering that would provide exits for SoftBank Vision Fund 2, Novo, BMS, Celgene, Evotec and Pivotal BioVenture Partners.
Daily Deal Round Up: September 7, 2021
Channel Talk, Segari and Borneo are all among the companies that have raised corporate venture capital, while Tepco celebrated an exit with the acquisition of Me:New.
Daily Deal Round Up: September 3, 2021
Versanis Bio secured $70 to commercialise a treatment licensed from Novartis, while Salesforce, Intel, Orange, Nike and Alphabet all celebrated exits.
Ally Therapeutics shuts down
Ally had raised $10m in seed funding from investors including UCB but disappointing animal studies led the company to be wound down.
Cardior catches $76m in series B round
Bristol Myers Squibb returned to reinvest in the cardiac disease therapy developer having backed its 2017 series A round with Boehringer Ingelheim.
Dice Molecules comes up trumps with $60m
The series C1 round pushed the Sanofi and Alexandria Real Estate Equities-backed oral therapeutics developer’s total funding to about $200m.
Daily Deal Round Up: August 24, 2021
TXOne Nertworks has added $12.9m to its coffers, while C3 has pushed its series B round to $90m thanks to a $10m extension.
Daily Deal Round Up: August 20, 2021
M12 backed three deals in recent days, including a $50m series D round for Split.io that also featured fellow corporates Atlassian and ServiceNow.
Daily Deal Round Up: August 6, 2021
JD Health has backed a $93m series D round for Rimag, while a couple of India-based startups delivered exits.
Hopin hatches $450m series D plan
Salesforce and Slack were among a consortium of new and existing backers for Hopin’s series D round, which comes only five months after a $400m series C.
Arise attracts Metrodata Electronics
The fund has achieved a first close towards its $40m target, having been formed by MDI Ventures and Finch Capital in November last year.
Meike is energised by $155m
The money was split across series A and A-plus rounds and came from investors including Chint and Sinopec.
Berry Oncology picks series B1 investors
China Merchants Capital has co-led a series B round sized at almost $99.2m that also attracted existing shareholder Legend Capital.